PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
ESC Congress Rome 2016
Bococizumab exits the PCSK9 stage:
A response from PCSK9 Forum Editors

Pfizer announced on Tuesday, 1st November that it was discontinuing development of bococizumab, its PCSK9 inhibitor.

According to the press release, the Company stated that: ‘The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders'.

PCSK9 Forum Editors discuss the implications of this outcome, especially in the light of the recent European Society of Cardiology and European Atherosclerosis Society Consensus statement providing practical guidance for the use of PCSK9 inhibitors.

Read the report »
Henry Ginsberg

John Chapman

ESC/EAS Task Force consensus statement on the use of PCSK9 inhibitors: https://www.ncbi.nlm.nih.gov/pubmed/27789571
New and updated edition of our popular therapeutic guide

A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition.

Read online » Download now »

Forward to colleagues »
  New eBook
Click here to forward this email to a colleague
Questions & Answers
Why are new treatments needed?
Read the full answer and other questions on the PCSK9 Forum »
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.